Biogen Idec, Inc. (NASDAQ:BIIB)

This one seems like cheating.

There are currently 270 BIIB shares in my "fund" with break-even of around 71.89 USD. http://caps.fool.com/Blogs/fund-trades/678775.

The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.

I feel that Tysabri's proven track-record over the past five years, as a prime treatment for multiple sclerosis, is providing real and worthwhile results for a very significant number of people, who must live with this otherwise 'incurable' disease.

new mgt, cutting costs, refocusing investments

Upward Momentum

BIIB is a good investment because it does not depend on reviews of brokers and experts such as Zacks. Take for example NKBP: Zacks gives it as "strong buy" for the past nine months, in fact NKBP continues to fall

Trendspotter

takeover target!

Great pipeline - 5 filings over next few years. Nimble size and new leadership will further focus this company and drive continued earnings growth.

With the house in order, the pipeline chugging along and Icahn placated (one hopes), this should be a good long-term gainer.

Buy. Good momentum and PEG.

Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri and Avonex will go down. Even the new drug, Fampridine will struggle.

http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5

Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS.

http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspx

Or, www.ctv.ca Search “CCSVI”

And www.ccsvivictory.club.officelive.com check “conflicts of interest” tab

Cutting back on R&D to help short term earnings at the expense of long term earnings (Ichann infleuence). Not a good move with competitors moving into same space

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 10/19.

Doing fairly well in the crisis, if they continue with the same management and research stays up-to-date it will have a good future

Three to four companies looking to buy BIIB for new drug pipeline.

This stock will be one of the few companies who will benefit from Obama's Universal Healthcare

Numerous competitors entering the MS therapeutic field with several potential oral drugs on the horizon. Significant loss of market share will erode BIIB revenues by 2010.